品牌 |
Leading Biology | 貨號(hào) |
AMM02556G |
產(chǎn)品分類 |
Monoclonal Antibodies | 研究領(lǐng)域 |
|
產(chǎn)品概述 |
We constantly strive to ensure we provide our customers with the best antibodies. As a result of this work we offer this antibody in purified format.
We are in the process of updating our datasheets. If you have any questions regarding this update, please feel free to contact our technical support team.
This product is a high quality ISG15 Antibody (N-term)).
|
||
分子量 |
17888 Da
|
||
細(xì)胞定位 |
Antigen Cellular Localization:
Cytoplasm. Secreted. Note=Exists in three distinct states: free within the cell, released into the extracellular space, or conjugated to target proteins
|
||
宿主 |
Mouse
|
||
種屬反應(yīng)性 |
Human
|
||
靶點(diǎn) |
This ISG15 antibody is generated from a mouse immunized with a KLH conjugated synthetic peptide between 1-165 amino acids from the N-terminal region of human ISG15.
|
||
克隆號(hào) |
1031CT2.8.3
|
||
亞型 |
IgG1,k
|
||
通用名 |
G1P2, UCRP
|
||
基因ID |
|||
UniProt ID |
|||
功能 |
Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein. ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein. Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Can also isgylate: EIF2AK2/PKR which results in its activation, DDX58/RIG-I which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation- inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade therby inhibiting IFNA- induced JNK signaling. Exhibits antiviral activity towards both DNA and RNA viruses, including influenza A, HIV-1 and Ebola virus. Restricts HIV-1 and ebola virus via disruption of viral budding. Inhibits the ubiquitination of HIV-1 Gag and host TSG101 and disrupts their interaction, thereby preventing assembly and release of virions from infected cells. Inhibits Ebola virus budding mediated by the VP40 protein by disrupting ubiquitin ligase activity of NEDD4 and its ability to ubiquitinate VP40. ISGylates influenza A virus NS1 protein which causes a loss of function of the protein and the inhibition of virus replication. The secreted form of ISG15 can: induce natural killer cell proliferation, act as a chemotactic factor for neutrophils and act as a IFN-gamma-inducing cytokine playing an essential role in antimycobacterial immunity.
|
||
總結(jié) |
Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein. ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein. Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Can also isgylate: EIF2AK2/PKR which results in its activation, DDX58/RIG-I which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation- inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade therby inhibiting IFNA- induced JNK signaling. Exhibits antiviral activity towards both DNA and RNA viruses, including influenza A, HIV-1 and Ebola virus. Restricts HIV-1 and ebola virus via disruption of viral budding. Inhibits the ubiquitination of HIV-1 Gag and host TSG101 and disrupts their interaction, thereby preventing assembly and release of virions from infected cells. Inhibits Ebola virus budding mediated by the VP40 protein by disrupting ubiquitin ligase activity of NEDD4 and its ability to ubiquitinate VP40. ISGylates influenza A virus NS1 protein which causes a loss of function of the protein and the inhibition of virus replication. The secreted form of ISG15 can: induce natural killer cell proliferation, act as a chemotactic factor for neutrophils and act as a IFN-gamma-inducing cytokine playing an essential role in antimycobacterial immunity.
|
||
儲(chǔ)存條件 |
Store at +4°C short term. For long-term storage, aliquot and store at -20°C or below. Stable for 12 months at -20°C. Avoid repeated freeze-thaw cycles.
|
||
應(yīng)用 |
WB, E
|
||
稀釋方法 |
WB~~1:8000
|
||
圖像 |
All lanes : Anti-ISG15 Antibody (N-term)) at 1:8000 dilution Lane 1: Hela whole cell lysate Lane 2: MCF-7 whole cell lysate Lysates/proteins at 20 μg per lane. Secondary Goat Anti-mouse IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 18 kDa Blocking/Dilution buffer: 5% NFDM/TBST. |
||
說明書 |
|||
數(shù)量 |
|
選擇 | 品牌 | 貨號(hào) | 產(chǎn)品名稱 | 規(guī)格 | 分類 | 研究領(lǐng)域 | 說明書 | 數(shù)量 | 目錄價(jià) | |
1 | Leading Biology | APG01369G | VEGF (Vascular Endothelial Growth Factor) Antibody - Without BSA and Azide | 100 μg | Monoclonal Antibodies |
|
¥4950.00 | 訂購 詢價(jià) | ||
2 | Leading Biology | AMM07627G | RIN2 Antibody (monoclonal) (M01) | 100 μg | Monoclonal Antibodies |
|
¥4950.00 | 訂購 詢價(jià) | ||
3 | Leading Biology | APR15980G | FGG Antibody | 100 μl | Monoclonal Antibodies |
|
¥5450.00 | 訂購 詢價(jià) | ||
4 | Leading Biology | AMM05161G | GOB5 / CLCA1 Antibody (clone 1C4) | 50 μg | Monoclonal Antibodies |
|
¥5450.00 | 訂購 詢價(jià) | ||
5 | Leading Biology | APR17667G | ORAI1 Antibody [3F6H5] | 0.1 mg | Monoclonal Antibodies |
|
¥6950.00 | 訂購 詢價(jià) | ||
6 | Leading Biology | APR11118G | HIV-1 p24 Antibody [7F4] (biotin) | 0.1 mg | Monoclonal Antibodies |
|
¥6950.00 | 訂購 詢價(jià) |
微信掃描二維碼,隨時(shí)隨地與小諾親密接觸,精彩活動(dòng),勁爆優(yōu)惠,觸手可得!